Stockscreener 앱 받기
0.4014
6.65%
-0.0286
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz
10 Stocks Under $1 That Will Explode - Insider Monkey
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Can Sangamo Therapeutics Inc. stock attract ESG capital inflowsEarnings Growth Report & High Accuracy Buy Signal Tips - Улправда
Is Sangamo Therapeutics Inc. stock oversold or undervaluedWeekly Trend Recap & Daily Growth Stock Investment Tips - Улправда
Why Sangamo Therapeutics Inc. stock remains resilient2025 Momentum Check & Community Shared Stock Ideas - Улправда
Can Sangamo Therapeutics Inc. stock weather global recessionOptions Play & Long-Term Growth Portfolio Plans - Улправда
Surprises Report: How Sangamo Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Technicals & Consistent Profit Trade Alerts - ulpravda.ru
Is Sangamo Therapeutics Inc. stock a contrarian buyMarket Trend Review & Long-Term Growth Stock Strategies - Улправда
Can Sangamo Therapeutics Inc. stock sustain market leadership2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Inflation Data: How Sangamo Therapeutics Inc. stock compares to industry benchmarks2025 Dividend Review & High Win Rate Trade Tips - Улправда
How Sangamo Therapeutics Inc. stock performs in weak economy2025 Risk Factors & Weekly High Momentum Picks - ulpravda.ru
How resilient is Sangamo Therapeutics Inc. stock in market downturnsJuly 2025 WrapUp & Low Drawdown Trading Techniques - Улправда
Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure billMarket Weekly Review & AI Forecast Swing Trade Picks - Улправда
Is Sangamo Therapeutics Inc. stock attractive for retirement portfoliosFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it a smart choice when deciding what to buy. - ulpravda.ru
Will Sangamo Therapeutics Inc. stock reach Wall Street targets2026 world cup usa national team final top scorers possession football expert forecast preview - Улправда
Sangamo Therapeutics (HAM:GBY) 9-Day RSI : 29.67 (As of Jan. 05, 2026) - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Sangamo Therapeutics (HAM:GBY) Preferred Stock - GuruFocus
Sangamo Therapeutics Inc (HAM:GBY) DCF Valuation - GuruFocus
Sangamo Therapeutics Inc Stock Baskets - GuruFocus
Sangamo Therapeutics (HAM:GBY) Intrinsic Value: Projected F - GuruFocus
Sangamo rises after trial data for Fabry disease therapy - MSN
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда
Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®
Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда
Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com
Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus
Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat
Sangamo Therapeutics Earnings Notes - Trefis
Sangamo reports positive Fabry disease gene therapy results - MSN
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo receives U.S. FDA Fast Track Designation to ST-503 - MSN
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyLife Science Industry News - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
4.73%
0.92%
자본화:
|
볼륨(24시간):